The USA-India Chamber of Commerce will host the annual ‘US-India BioPharma and Healthcare Summit’ here on June 23, which will focus on India’s potential to become a hub of innovation in the field of bio-pharma.

The summit will focus on issues such as overcoming barriers to building collaborative partnerships between Indian and global companies, drug discovery and development and restructuring R&D to maximise productivity and clinical research.

In attendance during the day-long summit will be industry honchos from India and the US, including senior leadership from major pharma companies such as Abbott, AstraZeneca, Sanofi, Johnson & Johnson, Pfizer, Merck and Bristol-Myers Squibb.

Over 30 Indian companies will be participating in the event, which will feature speakers such as Jubilant Life Sciences Co-Chairman, Mr Hari Bhartia, Biocon Chairman, Ms Kiran Majumdar Shaw, and Medanta Chairman, Mr Naresh Trehan, besides professors from Harvard and Tufts University.

“Our annual summit is a purpose-driven initiative to foster innovation and partnerships in the global bio-pharma industry,” the USA-India Chamber of Commerce President, Mr Karun Rishi, said in a statement.

Pfizer’s Global Head of R&D, Mr Mikael Dolsten, said biopharma and biotech companies have a strong interest in the continued growth of India’s innovative drug research industry to improve public health in India and the world and the summit provides a platform to forge partnerships between global bio-pharma and Indian healthcare firms.

Related Topics